Clinical trials
System Lupus Erythematosus(SLE) clinical trials
Below are recruiting system lupus erythematosus(sle) clinical trials, each written for real people, not researchers. We’re tracking 216 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07611747RecruitingPhase 4
Ultrasound Screening to Prevent Heart Disease in Rheumatic Patients
This study tests whether using ultrasound to look at arteries in the neck can help prevent heart attacks and strokes in people with inflammatory joint diseases like rheumatoid arthritis or lupus. Researchers will use the results to guide treatment decisions.
Alicante, AlicanteAges 50 years+ - NCT07598396RecruitingPhase 2
Mosunetuzumab for systemic lupus erythematosus treatment
This study tests a new drug called mosunetuzumab in people with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body's own tissues. The drug is designed to help control the immune response and reduce lupus symptoms, including kidney involvement if present.
Salvador, Estado de BahiaAges 18 years+ - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT07575347Recruiting
Gum Disease and Rare Kidney Disorders Study
This study explores whether people with certain rare kidney diseases or chronic kidney problems have more gum disease than others. Researchers will examine your teeth and gums to understand the connection and help improve care for people with kidney conditions.
BucharestAges 18 years+ - NCT07564596RecruitingPhase 1/Phase 2
A Study of Budoprutug for Systemic Lupus Erythematosus
This trial tests budoprutug, an experimental drug, to see if it helps people with systemic lupus erythematosus (SLE) whose disease is not well controlled by current treatments. The drug targets immune cells that may be driving the disease.
Mianyang, SichuanAges 18–65 - NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Nanjing, JiangsuAges 18–70 - NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07523542RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Treatment-Resistant Lupus
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Shenzhen, GuangdongAges 18–70 - NCT07517536Enrolling by invitation
CHT105 treatment for hard-to-treat lupus kidney disease
This study tests a new medicine called CHT105 for lupus patients whose kidney disease hasn't improved with standard treatments. The medicine targets specific immune cells that may be driving the kidney damage.
Nanjing, JiangsuAges 18–65 - NCT07509892RecruitingPhase 2
Testing TQH3906 for people with active lupus
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
Bengbu, AnhuiAges 18–74 - NCT07515014RecruitingPhase 2
Testing E6742 in Systemic Lupus Erythematosus
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Bengbu, AnhuiAges 18–75 - NCT06106893RecruitingPhase 1/Phase 2
Study of CD19 CAR-γδT cells for active lupus
This trial is testing a new type of immune cell therapy (called CD19 universal CAR-γδT cells) for people with active lupus that hasn't been well controlled by standard treatments. The goal is to see if these specially designed cells can calm the immune system and reduce lupus symptoms.
Wuhan, HubeiAges 18–70 - NCT06106906RecruitingPhase 1/Phase 2
CD19 CAR-T for Active Lupus
This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.
Wuhan, HubeiAges 18–70 - NCT07490041RecruitingEarly Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Hangzhou, ZhejiangAges 5 years+ - NCT07491900RecruitingPhase 1
Study of HB2198 for lupus with moderate to severe symptoms
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
BrisbaneAges 18–65 - NCT07483346RecruitingPhase 1
Testing IASO-782 for systemic lupus erythematosus
This trial tests a new medicine called IASO-782 for people with systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms when added to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT07447986RecruitingPhase 2
Testing a New Injection for Lupus (SLE)
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT07444307RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
Hefei, AnhuiAges 18–65 - NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Beverly Hills, CaliforniaAges 18–75 - NCT07430306RecruitingPhase 3
Study of anifrolumab for lupus patients not yet on strong treatments
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
Anniston, AlabamaAges 18–70 - NCT07425730Recruiting
Heart problems in childhood lupus study
This study looks at early heart function problems in children with lupus to find those at risk for severe disease. It may help doctors identify and treat severe lupus sooner.
Shanghai, Shanghai MunicipalityAges 7–17 - NCT07432334RecruitingPhase 1
CAR T-cell therapy for hard-to-treat lupus
This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.
HanoiAges 16–55 - NCT07409181RecruitingPhase 2
Testing an experimental pill for active lupus (SLE)
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Beverly Hills, CaliforniaAges 18–74
Hear when a new System Lupus Erythematosus(SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for system lupus erythematosus(sle)?
- Yes. Clin2 currently lists 216 recruiting system lupus erythematosus(sle) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a system lupus erythematosus(sle) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a system lupus erythematosus(sle) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.